Home > Press > NanoViricides Becomes a Member Of Alliance for Biosecurity
NanoViricides, Inc., a nano-biopharmaceutical company specializing in the development of novel therapeutics to treat life-threatening viral infections, announced today that it has joined the Alliance for Biosecurity, an association comprised of a leading non-profit biosecurity organization and 14 other biopharmaceutical companies committed to improving the nation's biosecurity through the development of medical countermeasures to address a range of bioterrorism and natural pandemic threats.
NanoViricides Becomes a Member Of Alliance for Biosecurity
WEST HAVEN, CT | Posted on April 16th, 2007
Anita Cicero, Executive Director of the Alliance for Biosecurity, commented, "We are delighted to welcome NanoViricides into the Alliance. The company's work in the cutting-edge field of Nanomedicine, combined with its interest in contributing constructive policy suggestions to bolster national Flexible Defense initiatives, will be a significant asset to the Alliance. NanoViricides shares our organization's goal of rapidly accelerating the research, development, and procurement of medical countermeasures that will be needed to respond to both destabilizing pandemics and bioterrorism attacks. With NanoViricides' help, the Alliance will continue its efforts to maximize the promise of Project BioShield and the new Pandemic and All Hazards Preparedness Act."
"Our Rapid Response technologies fit in well with the Flexible Biodefense initiatives that are part of recent US Government acts," said Anil R. Diwan, Ph.D., President, NanoViricides, Inc.
"NanoViricides is honored to be associated with this prestigious organization whose strong membership, comprised of the principal actors in the BioSecurity field, includes some of the most prestigious pharma and biotechnology companies in the world," added Dr. Eugene Seymour, CEO, NanoViricides, Inc.
In other news, NanoViricides, Inc. announced that it has been informed that the nominating NASD member firm has responded to NASD comments on the form 15c2-11submission for NanoViricides to be listed on the over the counter bulletin board (OTC-BB).
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
About the Alliance for Biosecurity- http://www.allianceforbiosecurity.org
The Alliance for Biosecurity is a collaboration among the Center for Biosecurity of the University of Pittsburg Medical Center, pharmaceutical companies, and biotechnology companies working to develop new technologies and vaccines and medicines for the Strategic National Stockpile. The Alliance seeks to engage government in a public-private partnership to usher in a new era in the prevention and treatment of severe infectious diseases that present global security threats. Member companies of the Alliance now include: Acambis, Inc., Avecia Biotechnology, Bavarian-Nordic, Cangene Corporation, DOR BioPharma, Inc., DynPort Vaccine Company, LLC, a CSC company, Elusys Therapeutics, Inc., Emergent BioSolutions, GlaxoSmithKline, Human Genome Sciences, Inc., Iomai Vaccines, NanoViricides, Inc., Novartis Vaccines & Diagnostics, Pfizer Inc., and PharmAthene, Inc.
For more information, please click here
Leo Ehrlich, 917-853-6440
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Iranian Scientists Separate Zinc Ion at Low Concentrations September 20th, 2014
Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014
SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014
Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014
IEEE International Electron Devices Meeting To Celebrate 60th Anniversary as The Leading Technical Conference for Advanced Semiconductor Devices September 18th, 2014
Biosensors Get a Boost from Graphene Partnership: $5 Million Investment Supports Dozens of Jobs and Development of 300mm Fabrication Process and Wafer Transfer Facility September 18th, 2014
Toward making lithium-sulfur batteries a commercial reality for a bigger energy punch September 17th, 2014
NEI Corporation and PneumatiCoat Technologies Sign Agreement to Jointly Develop and Market New Materials for Lithium-ion Batteries September 12th, 2014